ChartMill assigns a Buy % Consensus number of 85% to ELVN. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-07-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-16 | Baird | Maintains | Outperform -> Outperform |
| 2025-06-16 | Goldman Sachs | Initiate | Buy |
| 2025-05-16 | Jones Trading | Maintains | Buy -> Buy |
| 2025-05-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-13 | BTIG | Initiate | Buy |
| 2024-11-15 | Baird | Maintains | Outperform -> Outperform |
| 2024-10-31 | Jones Trading | Initiate | Buy |
| 2024-10-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-09 | HC Wainwright & Co. | Initiate | Buy |
| 2024-06-11 | Baird | Initiate | Outperform |
| 2024-04-09 | Mizuho | Initiate | Buy |
| 2023-03-29 | Jefferies | Initiate | Buy |
| 2023-03-03 | TD Cowen | Initiate | Outperform |
16 analysts have analysed ELVN and the average price target is 41.48 USD. This implies a price increase of 90.71% is expected in the next year compared to the current price of 21.75.
The consensus rating for ENLIVEN THERAPEUTICS INC (ELVN) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.